Genital Chronic GVHD in Men after Hematopoietic Stem Cell Transplantation: A Single-Center Cross-Sectional Analysis of 155 Patients  by Mueller, Simon M. et al.
Biol Blood Marrow Transplant 19 (2013) 1574e1580American Society for Blood
ASBMT
and Marrow TransplantationClinical Research
Genital Chronic GVHD in Men after Hematopoietic Stem
Cell Transplantation: A Single-Center Cross-Sectional
Analysis of 155 Patients
Simon M. Mueller 1,*, Peter Haeusermann 1, Alicia Rovó 2, Joerg P. Halter 2,
Jakob Passweg 2, Peter Itin 2, André Tichelli 2
1Department of Dermatology, University Hospital Basel, Switzerland
2Department of Hematology, University Hospital Basel, SwitzerlandArticle history:
Received 21 March 2013
Accepted 8 July 2013
Key Words:
Male genital GVHD
Allogeneic HSCT
Late effectsFinancial disclosure: See Acknowl
* Correspondence and reprint re
ment of Dermatology, University H
Switzerland
E-mail address: muellersim@uh
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
We assessed the prevalence and clinical features of genital skin changes in men after allogeneic hemato-
poietic stem cell transplantation (HSCT) and evaluated the correlation between genital chronic graft-versus-
host disease (cGVHD) and other manifestations of cGVHD as well as sexual issues. In a cross-sectional cohort
study, 155 male recipients alive 1 year or more after HSCT were assessed during their annual follow-up
evaluation. Correlation between genital skin changes and other cGVHD manifestations was evaluated, and
post-transplantation sexual contentment and sexual functioning were assessed by 2 self-assessment ques-
tionnaires, including the 5-item version of the International Index of Erectile Function (IIEF-5) and the
modiﬁed Brief Sexual Symptom Checklist (mBSSC). Median time between HSCT and genital examination was
5.9 years (range, 1 to 30.3 years). Thirty-one of 155 patients (20%) presented with genital skin changes.
Twenty-one of those (13%) presented clinically inﬂammatory genital skin changes considered as genital
cGVHD: 12 had inﬂammatory (noninfectious) balanoposthitis, 6 had lichen sclerosiselike lesions, 5 had
phimosis, and 2 patients had more than 1 feature. Patients with inﬂammatory genital skin changes had
a signiﬁcantly higher coincidence of oral (P < .0001), ocular (P < .002), and/or cutaneous cGVHD (P < .026)
when compared with patients without genital lesions. The rate of IIEF-5 questionnaire response was 59% (91
of 155). Among them, 67% reported erectile dysfunction. Erectile dysfunction was signiﬁcantly more frequent
in patients with genital cGVHD (P ¼ .0075). Seventy-ﬁve of 155 patients (48%) answered the mBSSC ques-
tionnaire. Only 40% of them reported sexual contentment. Genital skin changes in male recipients after
allogeneic HSCT are frequent and seem to be an under-reported relevant late effect. Inﬂammatory genital skin
changes can be considered as a form of genital cGVHD often associated with manifestations of extragenital
mucocutaneous cGVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT)
has become the treatment of choice for deﬁnedmalignant and
nonmalignant hematological disorders [1]. With a growing
number of transplantations performed yearly and outcomes
continually improving over the last decades, the number of
long-term survivors is steadily increasing [2]. As a result,
general health status, the development of late events related
to HSCT, and quality of life have become major issues. Long-
term survivors expect to recover their initial heath status
after HSCT and lead normal lives with appropriate physical
and psychosocial functioning [3-5].
Among nonmalignant late effects, genital skin manifesta-
tions, and particularly genital chronic graft-versus-host dis-
ease (cGVHD) after HSCT, arise as crucial problems affecting
long-term survivors. The scarce existing information reports
mostly on female patients, showing a high prevalence of
approximately 25% to 49% of female HSCT survivors [6-8].
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dryness, burning, itching, and dyspareunia [9]. Female genital
cGVHD impairs quality of life, sexual function, and relation-
ship dynamics and is often associated with cGVHD of other
organs, especially skin and oral mucosa [8,10]. The median
time of onset is between 7 and 10 months after allogeneic
HSCT, but the ﬁrst genital symptoms may also appear years
later [7-9,11]. Useof a peripheral source of hematopoietic stem
cells seems to be the only independent risk factor for the
development of genital cGVHD [8,12].
Data on post-transplantation male genital skin manifes-
tations in general and on genital cGVHD in particular is
virtually lacking. Genital involvement in men was even
neglected in the National Institutes of Health consensus
publication [13]. To our knowledge, only 8 cases of male
genital cGVHD have been reported [14-20]. Among these
case reports, only 3 different features have been described:
phimosis, lichen sclerosiselike changes, and Peyronie’s
disease. Thus, more information is needed on male genital
cGVHD in terms of diagnosis, management, and prevention
in long-term survivors after HSCT. To quantify epidemiolog-
ical and clinical aspects of male genital skin manifestations
and genital cGVHD, we conducted a prospective cross-
sectional study in which we consecutively evaluated 155
men after HSCT at their annual follow-up visit.Transplantation.
Table 1
Patient Characteristics
Characteristic Value
Total number of patients 155
Median age at HSCT, yr (range) 42 (12-68)
Median age at time of control, yr (range) 50 (21-72)
Median time between HSCT and control, yr (range) 5.9 (1-30.3)
Disease
Acute leukemia 64 (41%)
Chronic myeloid leukemia 23 (15%)
Myelodysplastic syndrome, myeloproliferative
neoplasms
17 (11%)
Multiple myeloma 9 (6%)
Chronic lymphocytic leukemia, non-Hodgkin disease 22 (14%)
Others 20 (28%)
Disease risk status at HSCT
Standard 106 (73%)
High risk 40 (27%)
Total body irradiation 81 (57%)
Acute GVHD
No 59 (38%)
Yes 96 (62%)
Chronic GVHD
No 49 (32%%)
Yes 105 (68%)
Table 2
Post-Transplantation Genital Skin Changes
Type of Change
Genital changes
Absent 124 (80%)
Present 31 (20%)
Noninﬂammatory genital skin changes 10 (6%)
Melanotic macules on the glans penis 3
Postinﬂammatory hyperpigmentation of the glans 2
Unspeciﬁc acute irritative balanitis 2
Postinﬂammatory depigmentation of the penis 1
Genital vitiligo in generalized vitiligo 1
Penis deviation during erection (not objectiﬁed) 1
Inﬂammatory genital skin changes, possible GVHD 21 (13%)
Balanoposthitis 12 (8%)
Lichen sclerosiselike 6 (4%)
Phimosis 5 (3%)
More than 1 feature 2 (1%)
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Study Design
This cross-sectional cohort study on long-term survivors was conducted
in collaboration between the Divisions of Hematology and Dermatology of
the University Hospital Basel, Basel, Switzerland. The primary study goal
was to assess the prevalence and clinical features of post-transplantation
genital skin changes in men, to describe nonspeciﬁc (not consistent with
genital cGVHD) and speciﬁc (distinctive of genital cGVHD) genital skin
changes, and to evaluate the correlation between genital cGVHD and any
other cGVHD manifestations. As a secondary study goal, we evaluated the
impact of genital skin manifestations on post-transplantation sexual issues.
Patients provided written informed consent to analyze their data on disease,
treatment, and outcome, including late complications reported anony-
mously to the registry. Clinical surveillance of HSCT recipients was approved
by local institutional review boards. Patient characteristics, HSCT condi-
tioning regimens, and clinical outcome data were collected prospectively
and stored in the local institution database registry.
We included male patients with a follow-up of 1 year or longer since
allogeneic HSCT between October 2010 and December 2011 who agreed to
undergo a complete dermatological evaluation, including genital skin exam-
ination, during their annual follow-up evaluations in our outpatient clinic.
During this period, 454 patients (285male patients) presented for the annual
evaluation, and 155 of themwere included in the study. Reasons for exclusion
were either patient refusal or time constraints. Patient complete pre- and
post-transplantation dermatological history was assessed, and a complete
skin examination including the genital area was performed. Data on pre-
transplantation genital skin examination was not available. During the study
period, 2 dermatologists experienced in the ﬁeld of HSCTwere involved. Each
patientwas examinedby1 of these 2dermatologists. Biopsieswere takenonly
to rule outmalignancies in speciﬁc clinical situations. Diagnosis and staging of
cGVHD, including skin changes of cGVHD, were assessed according to the
National Institutes of Health consensus criteria [13].
During this visit, all participants received 2 standardized self-
assessment questionnaires addressing erectile dysfunction (International
Index of Erectile Function [IIEF-5]; see Appendix) [21] and other sexual
symptoms, such as loss of libido and orgasm disorders (modiﬁed Brief
Sexual Symptoms Checklist [mBSSC]; see Appendix) [22,23]. Patients ﬁlled
out the questionnaires on a voluntary basis.
Male genital manifestations were divided into 2 subgroups: nonin-
ﬂammatory (nonspeciﬁc) and inﬂammatory (speciﬁc) genital skin changes.
Noninﬂammatory genital skin changes included melanotic macules on the
glans penis, postinﬂammatory hyperpigmentation of the glans, unspeciﬁc
acute irritative balanitis, postinﬂammatory depigmentation of the penis,
genital vitiligo in generalized vitiligo, and penis deviation during erection.
Inﬂammatory genital skin changes included noninfectious balanoposthitis
(inﬂammatory changes of the glans and the foreskin), lichen sclerosiselike
changes, and phimosis. Based on the description of female genital cGVHD,
we expected male genital cGVHD to be a chronic inﬂammatory process.
Therefore, for the present study, inﬂammatory genital skin changes were
considered distinctive of cGVHD.Study Population
In all 155 evaluated male recipients, dermatological history was
assessed followed by a skin and genital examination. The response rate of
the questionnaires was 59% (n ¼ 91) for the IIEF-5 and 52% (n ¼ 81) for the
mBSSC. The characteristics of all patients included in the study are
summarized in Table 1. The median age at transplantation and at the time of
study on genital changes were 42 years (range,12 to 68) and 50 years (range,
21 to 72), respectively. The median time between transplantation and
follow-up visit with genital examination was 5.9 years (range, 1 to 30.3).
Most patients underwent transplantation for acute leukemia (64 of 155;
41%), 81 of 155 patients (57%) were conditioned with total body irradiation,
96 patients (62%) had acute GVHD (skin, 78; gut, 40; liver, 26), and 105
patients (68%) had cGVHD (skin, 41; oral mucosa, 37; ocular, 14; liver, 25;
lung, 10; musculoskeletal, 8; gastrointestinal, 7; renal, 2; cardiac, 1).
To compare patients with and without inﬂammatory genital skin
changes, we used the nonparametric Mann-Whitney U rank test. The impact
between risk factors and the onset of genital skin changes were evaluated
using a linear regression analysis. Differences between the results of
comparative tests were considered signiﬁcant when 2-sided P < .05.
Statistical analysis was performed using SPSS Statistics, version 20 (IBM,
Armonk, NY).
RESULTS
Pretransplantation Dermatological and Genital History
The dermatological and genital history of the 155 patients
before HSCT reveals that 3 patients had inﬂammatory
dermatological diseases: 2 suffered from plaque psoriasis
and 1 had alopecia areata universalis. Fifteen patients had
a history of genital skin manifestation: phimosis (n ¼ 11),
condylomata acuminata (n ¼ 2), melanotic macules (n ¼ 1),
lichen sclerosiselike lesions (n ¼ 1), and undeﬁned (n ¼ 1).
One of 2 patients with condylomata acuminata also had
a history of gonorrhea. Twenty-six patients were circumcised
before HSCT.
Genital Skin Manifestation after HSCT
We found post-transplantation genital skin changes in 31
of 155 patients (20%). Ten of 31 patients (32%; 6% from total)
presented noninﬂammatory and 21 (68%; 13% from total)
inﬂammatory genital skin changes (Table 2). The inﬂamma-
tory subgroup was considered as consistent with cGVHD: 12
patients showed clinical features of inﬂammatory balano-
posthitis (Figure 1A,B), 6 patients lichen sclerosiselike
features (Figure 1C), and 5 patients phimosis (Figure 1D).
Two patients had more than 1 inﬂammatory lesion. From the
21 patients with genital cGVHD, all but 2were uncircumcised
and 7 were reported to be symptomatic (eg, painful sexual
intercourse, burning). One patient (patient 51) with inﬂam-
matory balanoposthitis and subtotal phimosis had under-
gone a skin biopsy to rule out malignancy. Histologically, we
found aminor spongiotic alteration of the epidermis without
Figure 1. Examples of post-transplantation inﬂammatory genital skin changes. (A) Inﬂammatory (noninfectious) balanoposthitis with reddish “cayenne-pepper
spots” on the glans penis and partial phimosis. (B) Shiny plaques on the glans penis and the inner layer of the foreskin. (C) Lichen sclerosiselike skin changes with
erythematous and whitish sclerotic areas on the foreskin. (D) Phimosis.
Table 3
Comparison between Patients with and without Inﬂammatory Genital Skin
Changes
Parameter Without
Inﬂammatory
Genital Skin
Changes
With
Inﬂammatory
Genital Skin
Changes
P
Number of patients 134 21
Total body irradiation 71 (53%) 10 (48%) .599
Disease
Acute leukemia 56 (42%) 8 (38%) .958
Chronic myeloid leukemia 20 (15%) 3 (14%)
Myelodysplastic syndrome,
myeloproliferative
neoplasms
14 (10%) 3 (14%)
Myeloma 7 (5%) 2 (9%)
Chronic lymphocytic
leukemia, non-
Hodgkin disease
19 (14%) 3 (14%)
Others 18 (13%) 2 (9%)
Disease status
Standard 92 (73%) 14 (70%) .779
High risk 34 (27%) 6 (30%)
Overall acute GVHD 81 (60%) 15 (71%) .335
Acute GVHD by localization
Cutaneous 68 (53%) 10 (56%) .821
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could be ruled out. In no other patient did we detect sus-
pected tumor changes.
For patients who presented with inﬂammatory genital
cGVHD (n¼ 20), treatment was started and a clinical follow-
up performed after 4, 8, and 12 weeks. They were treated
once or twice daily with a highly potent topical corticoste-
roid (class III/IV). One case with an unsatisfactory response
after 10weekswas switched to topical pimecrolimus 5%. This
patient showed complete recoverywithin 4weeks. In case of
phimosis or unsatisfactory response to local therapy within
12 weeks (3 patients with inﬂammatory balanoposthitis),
a circumcision was performed (n ¼ 4/5). Four patients
refused treatment of their genital lesions.
Details of the 21 patients with genital cGVHD are pre-
sented in Table 3. Five of the 21 patients had no other chronic
mucocutaneous GVHD manifestations. The other 16 patients
presented simultaneously with cutaneous, oral, and/or
ocular cGVHD manifestations. The subgroup with inﬂam-
matory genital skin changes did not differ from the patients
without genital GVHD with respect to conditioning regimen
(total body irradiation versus no total body irradiation),
primary disease, disease status before HSCT (standard versus
high risk), time interval between HSCT and genital exami-
nation, and presence of acute GVHD (GVHD grades 0 to I
versus grades II to IV) (Table 4). However, patients with
inﬂammatory genital skin changes presented a signiﬁcantly
higher prevalence of nongenital cGVHD (95% versus 68%, P ¼
.018), nonmucosal skin GVHD (28% versus 5%, P ¼ .026), oral
mucosal cGVHD (67% versus 17%, P < .0001), and ocular
mucosal cGVHD (36% versus 8%, P ¼ .002).Gut 36 (27%) 4 (22%) .637
Liver 21 (16%) 5 (28%) .225
Overall cGVHD 86 (65%) 19 (91%) .018
Oral mucosal cGVHD 23 (17%) 14 (67%) <.0001
Ocular cGVHD 9 (8%) 5 (36%) .002
Cutaneous cGVHD 27 (20%) 14 (67%) <.001Sexual Dysfunctions
Erectile dysfunction
Ninety-one of 155 patients (59%) returned the question-
naire on erectile function (IIEF-5). The basic characteristicsbetween patients who returned the questionnaire and those
who did not were not statistically different. Ten of the 91
patients (11%) who returned the questionnaire and 11 of 64
patients (17%) who did not return the questionnaire pre-
sented with genital cGVHD (P ¼ .26). From the 91 patients, 7
did not have any intercourse since HSCT. By deﬁnition, these
patients had a score below 5 (lowest score). The IIEF-5 score
Table 4
Description of 21 Patients with Inﬂammatory Genital Skin Changes
Patient No. Age at
HSCT (yr)
Disease TBI Pretransplantation Genital
Skin Manifestation
Genital cGVHD* Organ
cGVHD
Cutaneous cGVHDy Oral cGVHD Ocular cGVHD
5 62 AML No None Balanoposthitis Yes None None None
14 46 AML Yes Cone Balanoposthitis Yes None Lichen-type Keratoconjunctivitis sicca
18 50 B cell lymphoma Yes Circumcised Lichen sclerosiselike Yes Depigmentation (vitiligo) and z Lichen-type and xerostomia Keratoconjunctivitis sicca
19 25 MDS Yes None Balanoposthitis Yes z Lichen-type Keratoconjunctivitis sicca
31 32 CML No None Balanoposthitis Yes z Lichen-type Keratoconjunctivitis sicca
32 25 Myeloma No None Balanoposthitis Yes Sclerotic and z Lichen-type Keratoconjunctivitis sicca
43 33 DLBCL No None Lichen sclerosiselike Yes z Lichen-type Keratoconjunctivitis sicca
51 53 B cell lymphoma No None Balanoposthitis Yes Poikiloderma; lichen planuselike; sclerotic;
morphea-like
None Keratoconjunctivitis sicca
68 61 ALL Yes None Balanoposthitis and lichen
sclerosiselike
Yes Sclerotic None Keratoconjunctivitis sicca
80 39 CML Yes None Balanoposthitis Yes Lichen planuselike, poikiloderma, longitudinal
nail ridging and pterygium unguis and z
Hyperkeratotic plaques Keratoconjunctivitis sicca
98 62 MCL No None Phimosis Yes None None None
101 47 No None Lichen sclerosiselike Yes z Lichen-type Keratoconjunctivitis sicca
109 50 AML Yes Phimosis Phimosis (worsening) Yes Sclerotic; morphea-like and z Lichen-type None
110 46 AML Yes None Balanoposthitis Yes None None None
111 62 CML No None Balanoposthitis Yes Longitudinal ridging, splitting of nails, and z Lichen-type None
114 12 ALL Yes None Phimosis Yes z Lichen-type None
120 38 MDS Yes None Balanoposthitis Yes Depigmentation and z Lichen-type None
123 42 Myeloma No Phimosis Balanoposthitis and
worsening phimosis
Yes Poikiloderma; lichen planuselike; sclerotic and z Lichen-type Keratoconjunctivitis sicca
133 49 AML Yes None Phimosis Yes Sclerotic; depigmentation (vitiligo) and z Hyperkeratotic plaques None
138 59 MDS No None Lichen sclerosiselike Yes None None None
147 32 T cell-ALL Yes Circumcised Lichen sclerosiselike No None None None
TBI indicates total body irradiation; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; MDS, myelodysplastic syndrome; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell
lymphoma.
* Post-transplantation inﬂammatory genital skin changes, consistent with genital cGVHD.
y Diagnostic and distinctive features according to National Institutes of Health consensus group [13].
z Cutaneous cGVHD including as a “diagnostic” sign oral cGVHD such as oral lichenetype features or hyperkeratotic plaques (according to National Institutes of Health consensus group [13]).
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(median score, 19). Of these 84 patients, 4 (5%) had severe,
12 (14%) moderate, 14 (17%) mild to moderate, and 24 (29%)
had mild erectile dysfunctions. In brief, from the 84 patients,
30 (36%) reported normal erectile function and 54 (67%)
indicated erectile dysfunction after HSCT. The answers from
the 10 patients with genital cGVHD who returned the IIEF-5
questionnaire revealed that 3 did not have any intercourse, 2
patients had moderate erectile dysfunction, 3 mild to
moderate erectile dysfunction, and 2 patients had normal
erectile function. Of the 10 patients with genital cGVHD, 8
(80%) had erectile dysfunction (score<17) comparedwith 29
of 81 patients (36%) without genital cGVHD (P ¼ .0075).
Sexual contentment
From the entire cohort, 81 patients (52%) returned the
mBSSC, but only 75 (48%) ﬁlled it out. Thirty patients re-
ported sexual contentment, whereas 45 patients reported
dissatisfaction. There was no difference between patients
with and without genital cGVHD: 5 of 8 patients (62%) with
and 40 of 67 patients (59%) without genital cGVHD were not
satisﬁedwith their sexual lives (P¼ .57). From the 75 patients
reporting on sexual contentment, only about one half of
them responded to the 6 additional questions on sexuality:
23 of 39 (59%) avoided sexuality, 31 of 44 (70%) had no
interest in sex, 26 of 41 (63%) reported erectile problems, 17
of 38 (45%) experienced premature ejaculation, 20 of 40
(50%) had problems with orgasm, 6 of 36 (27%) reported pain
during the intercourse, and 9 of 39 (23%) had concerns about
the length of the penis. Because of the low number of
respondents, we did not perform a statistical comparison
between patients with and without genital cGVHD.
DISCUSSION
Late genital skin manifestation is still an unrecognized
issue in men treated with allogeneic HSCT. Here, we present
the results of the ﬁrst large cross-sectional study focusing on
epidemiology and clinical presentation of male genital skin
manifestations and genital cGVHD. Overall, we found post-
transplantation genital skin changes in 31 of 155 (20%)
long-term survivors. Inﬂammatory genital skin changes were
identiﬁed in 21 of these patients (13%). These inﬂammatory
genital changes presenting clinically as balanoposthitis, phi-
mosis, and lichen sclerosiselike skin changes were, in
analogy of female genital skin lesions, considered as possible
male genital cGVHD. Moreover, patients with inﬂammatory
genital skin changes more frequently reported erectile
dysfunction, but did not report worse sexual contentment
when compared with patients without inﬂammatory genital
lesions.
Thus far, diagnosis, management, and surveillance of
genital cGVHD in male recipients have not been deﬁned [24].
Lichen sclerosiselike skin changes and phimosis have been
described in single case reports as a possible genital mani-
festation of cGVHD [15,17-20]. There are compelling argu-
ments that the observed inﬂammatory genital lesions in male
recipients are related to cGVHD. The close relationship
between the inﬂammatory genital skin changes and non-
genital organ manifestation of cGVHD supports this premise.
In women, the correlation between organ manifestations of
cGVHD and genital cGVHD is well recognized [7,8]. It is likely
that the inﬂammatory changes observed in our cohort reﬂect
manifestations of male genital cGVHD. In our study pop-
ulation, inﬂammatory balanoposthitis (not consistent with
lichen sclerosiselike lesions), which has not been described inmale recipients after HSCT so far, was the most frequent
genital skin lesion. Nine of 12 observed patientswith that kind
of balanoposthitis presented with oral and/or ocular cGVHD,
and 7 of them had oral lichenetype cGVHD. In view of this
close clinical relationshipwith cGVHD and despite the lacking
histological proof, these inﬂammatory genital skin lesions are
more likely to be distinctive of genital cGVHD rather than
merely a coincidental inﬂammatory reaction. The deﬁnitive
proof would be to histologically document a lichenoid
inﬂammatory pattern or sclerotic features (lichen planuse
like/lichen sclerosiselike).
The high level of consent among our long-term survivors
to be examined speciﬁcally for genital changes demonstrates
the interest of patients on this issue. During the dermato-
logical evaluation, many undiagnosed genital problems
became evident. This means a signiﬁcant number of patients
will not spontaneously report genital problems but will
appreciate examination when recommended during the
visit. Sexuality assessment is a much more intricate issue.
Nearly two thirds of the patients answered the questionnaire
on erectile dysfunction and about one half of the patients
answered the simple question on sexual contentment. Only
one third of the total cohort, however, responded to more
speciﬁc questions concerning their own sexuality. Patients
with possible genital cGVHD showed signiﬁcantly more
often erectile dysfunction but not worse sexual contentment
than patients without genital cGVHD. This apparent
discrepancy could be due to incomplete data on sexual
contentment. More likely, however, erectile dysfunction is
more directly related to genital skin changes than to sexual
contentment. Sexual life after HSCT is a complex situation in
which many other factors, such as gonadal insufﬁciency,
changed body image/relationship, weak physical condition,
anxiety, and depression, may play an important role.
Knowledge about genital skin changes and genital cGVHD
in men is clinically relevant. Although we did not observe
secondary genital skin malignancies in our cohort, the
occurrence of secondary cancer remains a concern. Excess of
squamous cell carcinoma of the skin and of oral cavity has
been demonstrated in patients with chronic skin and/or
mucosal GVHD [25]. Furthermore, inﬂammatory genital skin
lesions may reﬂect a premalignant condition. In men with
genital lichen sclerosis, premalignant or malignant condi-
tions can be observed in 5% to 10% [26-30].
So far, there are no treatment guidelines for male genital
cGVHD. Based on our local experience, topical application of
potent glucocorticoids (class III/IV) is safe and seems to be
efﬁcient in most cases. Alternatively, and in parallel with the
standard treatment of genital lichen sclerosis of both sexes,
topical calcineurin inhibitors could be used as monotherapy
or combined with topical glucocorticoids. However, we
recommend the use of topical calcineurin inhibitors only as
a short-term second-line therapy (4 to 12 weeks); malignant
transformation in nontransplantation patients has been
observed after long-term application for atopic dermatitis,
leading to a black box warning by the US Food and Drug
Administration and this remains as an ongoing controversy
[31-33]. In cases of complete phimosis or insufﬁcient
response to topical treatment, circumcision is the treatment
of choice.
Our study presents some limitations. First, no pre-
transplantation skin examination had been performed
systematically. Therefore, we cannot exclude that some
patients with post-transplantation skin changes already had
genital lesions before transplantation. However, according to
S.M. Mueller et al. / Biol Blood Marrow Transplant 19 (2013) 1574e1579 1579the patients’ histories assessed during the study, it is unlikely
that these patients had relevant genital skin changes before
HSCT. Second, inﬂammatory genital lesions were not
assessed by histology to prove the association with cGVHD.
Third, incomplete data collection on erectile dysfunction and
sexual life makes the interpretation with respect to the
genital changes difﬁcult. However, we could show that the
group of patients who did answer the questionnaires did not
differ from the patients who did not return their question-
naires. Our data clearly show that most patients agree to be
asked about and examined for genital skin changes, but only
some of them will answer by questionnaire on their sexual
lives.
In conclusion, we show for the ﬁrst time that inﬂamma-
tory genital skin changes in male long-term survivors after
allogeneic HSCT are relevant late effects and can be consid-
ered as a form of genital cGVHD. Genital cGVHD is often
associated with other mucocutaneous or ocular manifesta-
tions of cGVHD. Patients with inﬂammatory genital changes
seem to present more often with erectile dysfunctions;
however, we could not show any inﬂuence on sexual
contentment. All long-term survivors should be actively
asked about genital skin symptoms and at least annually
checked for genital skin changes. Referral for specialist
advice should be considered in patients with genital skin
lesions. Long-term surveillance of genital skin changes,
particularly with respect to secondary cancer detection,
should be included in the routine examination.
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IIEF-5 Questionnaire
This questionnaire includes 5 issues in relation to erectile
function: (1) How did you rate your conﬁdence that you
could get and keep an erection? (2) When you had an erec-
tion with sexual stimulation, how often were your erections
hard enough for penetration? (3) During sexual intercourse,
how often were you able to maintain your erection after you
had penetrated your partner? (4) During sexual intercourse,
how difﬁcult was it to maintain your erection to completion
of the intercourse? (5) When you attempted sexual inter-
course, how often was it satisfactory to you?
Each question was scored from 0 (not existing) to 5 (very
high). The IIFE-5 score is the sum of the responses to the 5
items. The overall score may range from 5 to 25. Scores from
0 to 4 must be documented, although they cannot be inter-
preted. Overall, erectile dysfunction was interpreted as
severe with a score between 5 and 7, moderate with a score
between 8 and 11, mild to moderate with a score between 12
and 16, and mild with a score between 17 and 21. There was
no erectile dysfunction when the score was 22 or higher.Modiﬁed Brief Sexual Symptoms Checklist
The mBSSC assesses sexual contentment, duration of
discontentment, and type of sexual problem with the
following questions:
1. Are you satisﬁed with your sexual function? If no,
please continue.
2. How long have you been dissatisﬁed with your
sexual function? Years, months, weeks?
3. Which problem(s) do you have? Multiple answers
are possible: if yes, then little, moderate, much?
3.1. I avoid sexuality.
3.2. Little or no interest in sex.
3.3. Problems with erection.
3.4. Ejaculating too early during sexual activity.
3.5. Taking too long, or not being able to ejaculate or have
orgasm.
3.6. Pain during sex.
3.7. Penile curvature during erection.
3.8. Worries about penis size.
